Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-15T23:19:52.916Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy and Quality of Life in Patients with Schizophrenia and Schizoaffective Disorders Treated with Long-acting Paliperidone Palmitate: A Naturalistic Longitudinal Study

Published online by Cambridge University Press:  23 March 2020

A. Nivoli ,
L. Folini ,
L. Floris ,
M. Antonioli ,
F. Pinna ,
M. Paolo ,
C. Bernardo  and
L. liliana
A. Nivoli
Affiliation:
University of Sassari, Department of Psychiatry, Sassari, Italy
L. Folini
Affiliation:
University of Sassari, Department of Psychiatry, Sassari, Italy
L. Floris
Affiliation:
University of Sassari, Department of Psychiatry, Sassari, Italy
M. Antonioli
Affiliation:
University of Sassari, Department of Psychiatry, Sassari, Italy
F. Pinna
Affiliation:
University of Cagliari, Department of Psychiatry, Cagliari, Italy
M. Paolo
Affiliation:
University of Sassari, Department of Psychiatry, Sassari, Italy
C. Bernardo
Affiliation:
University of Cagliari, Department of Psychiatry, Cagliari, Italy
L. liliana
Affiliation:
University of Sassari, Department of Psychiatry, Sassari, Italy

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Intramuscular paliperidone palmitate (PP) is a long-acting, atypical antipsychotic for ntramuscular (IM) administration in the treatment of patients with schizophrenia.

Objective

To study efficacy and quality of life in patients with schizophrenia and schizoaffective disorders treated with long-acting paliperidone palmitate.

Method

A non-randomized, prospective naturalistic study was performed in out-patients with schizophrenia and schizoaffective disorder unsuccessfully treated with oral antipsychotics. Efficacy of PP over time was evaluated by using BPRS 24-items (Brief Psychiatric Rating Scale) Quality of life was evaluated by the QL-Index (Quality of life Index) at T0 and at most recent visit (T1).

Results

Data were available for 16 outpatients consecutively prescribed PP and naturalistically treated attending at the Psychiatric Clinic, University of Sassari. Patients were predominantly male (n = 9; 56.2%), with schizophenia (n = 10; 62.5%). Three patients dropped out (18.8%). Mean time on PP treatment was 870.0 days (sd 217.02) at a mean PP maintenance dose of 97.82 ± 37.17 mg eq. BPRS mean total score at T0 was 55 (sd 14.5) and at T1 was 44.8 (sd 11.8). Ql-Index mean total score was 5 (sd 1.6) at T0 and 7.2 (sd 2.4) at T1. Paired sample test showed a statistically significant difference in deacreasing symptoms at BPRS over time (P = 0.009) and in improving Quality of life at QL-Index (P = 0.017). The analyses showed a significant improving at the following BPRS sub-items: Depression (P = 0.021), Hostility (P = 0.022), Suspiciousness (P = 0.005), Hallucinations (P = 0.050), Unusual thought content (P = 0.029), Self-neglet (P = 0.028), Conceptual disorganization (P = 0.044), Emotional withdrawal (P = 0.028) and Distractibility (P = 0.014).

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster Walk: Schizophrenia and Other Psychotic Disorders–Part 4
Information
European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. S274
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.